# Study Evaluating the Safety and Tolerability of NSA-789

> **NCT00633048** · PHASE1 · COMPLETED · sponsor: **Wyeth is now a wholly owned subsidiary of Pfizer** · enrollment: 64 (estimated)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** NSA-789
- **DRUG:** placebo

## Key facts

- **NCT ID:** NCT00633048
- **Lead sponsor:** Wyeth is now a wholly owned subsidiary of Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-03
- **Primary completion:** 2008-05
- **Final completion:** 2008-05
- **Target enrollment:** 64 (ESTIMATED)
- **Last updated:** 2009-02-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00633048

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00633048, "Study Evaluating the Safety and Tolerability of NSA-789". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT00633048. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*